US equities
|
SPCX
$167.18
▲+5.17%
NVDA
$237.03
▲+1.32%
MU
$1,064.83
▼-0.94%
TSLA
$378.01
▲+2.00%
MSFT
$527.22
▲+1.87%
SNDK
$1,715.44
▼-0.26%
INTC
$116.62
▼-2.27%
META
$746.40
▲+2.52%
SPCX
$167.18
▲+5.17%
NVDA
$237.03
▲+1.32%
MU
$1,064.83
▼-0.94%
TSLA
$378.01
▲+2.00%
MSFT
$527.22
▲+1.87%
SNDK
$1,715.44
▼-0.26%
INTC
$116.62
▼-2.27%
META
$746.40
▲+2.52%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Tevogen Bio
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
March 20, 2024
From
Tevogen Bio
Via
Business Wire
Tickers
TVGN
Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
March 05, 2024
From
Tevogen Bio
Via
Business Wire
Tickers
TVGN
Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI
February 27, 2024
From
Tevogen Bio
Via
Business Wire
Tickers
TVGN
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
February 21, 2024
From
Tevogen Bio
Via
Business Wire
Tickers
TVGN
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
February 17, 2024
From
Tevogen Bio
Via
Business Wire
Tickers
TVGN
Tevogen Bio Announces $8 Million Equity Investment
February 15, 2024
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus
January 31, 2024
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Appoints Globally Prominent Physicist Specializing in Space Biology, COVID-19, and AI Democratization, Afshin Beheshti, to Advisory Board
January 29, 2024
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Expands Presence in Rapidly Emerging Field of Biotechnology AI: Files Patent Applications Related to AI-Driven T cell Target Identification and Receptor Engagement
December 19, 2023
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Appoints IT Expert and Leader Mittul Mehta as Chief Information Officer and Head of Tevogen.ai Initiative
October 23, 2023
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Congratulates Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund on Being Elected to Serve as President of the Global Virus Network
October 12, 2023
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Introduces Tevogen.ai to Enhance Patient Accessibility and Accelerate Innovation Leveraging Artificial Intelligence
October 10, 2023
From
Tevogen Bio
Via
Business Wire
Tevogen Bio will Present Positive Proof-of-Concept Trial Findings at the 5th Annual Allogeneic Cell Therapies Summit in Boston, MA
May 22, 2023
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Expresses Gratitude as CEO is Named Recipient of Boy Scouts of America Distinguished Citizen Award
May 11, 2023
From
Tevogen Bio
Via
Business Wire
Tevogen Bio CSO to Discuss Investigational T Cell Therapy at NOLA Conference Focused on Long COVID and COVID-Related Cancer Risk, Alongside Leading Oncology Experts
April 26, 2023
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Appoints Cell Therapy Expert Dr. Dolores Grosso as Global Clinical Development Lead to Accommodate Its Expanding Portfolio
January 04, 2023
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform
January 23, 2023
From
Tevogen Bio
Via
Business Wire
Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options
December 07, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis
December 01, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID
November 22, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio® Expresses Gratitude for 2023 Nobel Peace Prize Nomination of the Company and its Founding CEO Ryan Saadi in Recognition of its Novel Business Model to Alleviate Health Inequality
October 12, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio CEO Ryan Saadi and CSO Neal Flomenberg share White House concerns about emerging COVID-19 variants and impact on immunocompromised patients, and express commitment to accelerate development of company’s investigational COVID-19 therapy
October 27, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Appoints Esteemed Global Safety Management Expert Victor Sordillo to its Corporate Advisory Board
August 31, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Appoints Three Prominent Healthcare Leaders to its Board of Directors
August 17, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients
August 01, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D
July 07, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology
June 30, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board
June 23, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients
June 07, 2022
From
Tevogen Bio
Via
Business Wire
Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio
May 03, 2022
From
Tevogen Bio
Via
Business Wire
